The relationship between fetuin-a and bone mineral density in postmenopausal osteoporosis;Postmenapozal osteoporozda fetuin-a ve kemik mineral yoǧunluǧu arasındaki i̇lişki

Turkish Journal of Rheumatology

Volumn 28, Issue 3, 2013, Pages 195-201

  Sari, Aylin ^a   Uslu, Turan ^b  

^a Erenkoy Physical Medicine and Rehabilitation Hospital   (Turkey)

^b FATIH SULTAN MEHMET TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bone mineral density; Fetuin a; Postmenopausal osteoporosis

Indexed keywords

BIOLOGICAL MARKER; CALCIFEDIOL; FETUIN A;

ADULT; AGE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 84884182619     PISSN: 13090291     EISSN: 13090283     Source Type: Journal    
DOI: 10.5606/tjr.2013.2468     Document Type: Article

References (33)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
2. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38:S4-9.
3. Ketteler M, Wanner C, Metzger T, Bongartz P, Westenfeld R, Gladziwa U, et al. Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int Suppl 2003;S84-7.
4. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-29.
5. Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/ fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-41.
6. Adams CS, Mansfield K, Perlot RL, Shapiro IM. Matrix regulation of skeletal cell apoptosis. Role of calcium and phosphate ions. J Biol Chem 2001;276:20316-22.
7. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755-61.
8. Coen G, Ballanti P, Balducci A, Grandi F, Manni M, Mantella D, et al. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Am J Kidney Dis 2006;48:106-13.
9. Walker-Bone K, Dennison E, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2001;27:1-18.
10. Denecke B, Gräber S, Schäfer C, Heiss A, Wöltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 2003;376:135-45.
11. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H. Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. Osteoporos Int 2007;18:251-9.
12. Kirkpantur A, Altun B, Hazirolan T, Akata D, Arici M, Kirazli S, et al. Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients. Artif Organs 2009;33:844-54.
13. Janckila AJ, Lederer ED, Price BA, Yam LT. Tartrateresistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease. Clin Nephrol 2009;71:387-96.
14. Fiore CE, Celotta G, Politi GG, Di Pino L, Castelli Z, Mangiafico RA, et al. Association of high alpha2Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 2007;195:110-5.
15. Ix JH, Wassel CL, Bauer DC, Toroian D, Tylavsky FA, Cauley JA, et al. Fetuin-A and BMD in older persons: the Health Aging and Body Composition (Health ABC) study. J Bone Miner Res 2009;24:514-21.
16. Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk. Aliment Pharmacol Ther 2012;36:345-52.
17. Rasul S, Ilhan A, Reiter MH, Todoric J, Farhan S, Esterbauer H, et al. Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. Clin Endocrinol (Oxf) 2012;76:499-505.
18. Yuce M, Davutoglu V, Cakici M. Fetuin-A, osteoporosis and inflammation--proposal of possible mechanisms for vascular and valvular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25:2801.
19. Masi L. Epidemiology of osteoporosis. Clin Cases Miner Bone Metab 2008;5:11-3.
20. Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A regulation of calcified matrix metabolism. Circ Res 2011;108:1494-509.
21. Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. J Biol Chem 1999;274:28514-20.
22. Toroian D, Price PA. The essential role of fetuin in the serum-induced calcification of collagen. Calcif Tissue Int 2008;82:116-26.
23. Colclasure GC, Lloyd WS, Lamkin M, Gonnerman W, Troxler RF, Offner GD, et al. Human serum alpha 2HS-glycoprotein modulates in vitro bone resorption. J Clin Endocrinol Metab 1988;66:187-92.
24. Ashton BA, Smith R. Plasma alpha 2HS-glycoprotein concentration in Paget's disease of bone: its possible significance. Clin Sci (Lond) 1980;58:435-8.
25. Dickson IR, Bagga M, Paterson CR. Variations in the serum concentration and urine excretion of alpha 2HS-glycoprotein, a bone-related protein, in normal individuals and in patients with osteogenesis imperfecta. Calcif Tissue Int 1983;35:16-20.
26. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33.
27. Schinke T, Amendt C, Trindl A, Pöschke O, Müller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996;271:20789-96.
28. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-66.
29. Dellegrottaglie S, Sanz J, Rajagopalan S. Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med 2006;6:515-24.
30. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-67.
31. Jahnen-Dechent W, Schinke T, Trindl A, Müller-Esterl W, Sablitzky F, Kaiser S, et al. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 1997;272:31496-503.
32. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003;278:22144-52.
33. Chailurkit L, Kruavit A, Rajatanavin R, Ongphiphadhanakul B. The relationship of fetuin-A and lactoferrin with bone mass in elderly women. Osteoporos Int 2011;22:2159-64.